Cargando…

Cyclophosphamide and epirubicin-induced diabetes mellitus in breast cancer: A rare occurrence

Breast cancer is the leading cause of death in women. Epirubicin and cyclophosphamide (EC) is one of the chemotherapeutic regimens used for the treatment of breast cancer. We describe a case treated with EC regimen and who presented to us with symptoms suggestive of diabetes mellitus postchemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Pramod Kumar, Misra, Arup Kumar, Singh, Vikram, Gupta, Ajay, Saroha, Shrishti, Singh, Surjit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020776/ https://www.ncbi.nlm.nih.gov/pubmed/27651713 http://dx.doi.org/10.4103/0976-500X.189684

Ejemplares similares

Lesinurad: A significant advancement or just another addition to existing therapies of gout?
por: Gupta, Ajay, et al.
Publicado: (2016)

A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence
por: Sharma, Pramod Kumar, et al.
Publicado: (2018)

Gingival hyperplasia: Should drug interaction be blamed for?
por: Sharma, Pramod Kumar, et al.
Publicado: (2017)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2014)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

A systematic review of mucormycosis cases in COVID-19: Is it an unholy trilogy of COVID-19, diabetes mellitus, and corticosteroids?
por: Kumar, Rajesh, et al.
Publicado: (2022)

Pediatric pharmacovigilance in an institute of national importance: Journey has just begun
por: Sharma, Pramod Kumar, et al.
Publicado: (2017)

Distinct effects of epirubicin, cisplatin and cyclophosphamide on ovarian somatic cells of prepuberal ovaries
por: Marcozzi, Serena, et al.
Publicado: (2019)

Pleomorphic Lobular Carcinoma in a Male Breast: A Rare Occurrence
por: Rohini, Bhatia, et al.
Publicado: (2010)

Cyclophosphamide and epirubicin induce high apoptosis in microglia cells while epirubicin provokes DNA damage and microglial activation at sub-lethal concentrations
por: de la Hoz-Camacho, Rafael, et al.
Publicado: (2022)

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
por: Singh, Surjit, et al.
Publicado: (2016)

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007)

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients
por: Chen, Lu, et al.
Publicado: (2018)

An open-label, randomized, 10 weeks prospective study on the efficacy of vitamin D (daily low dose and weekly high dose) in vitamin D deficient patients
por: Singh, Vikram, et al.
Publicado: (2019)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

A Case of Drug-Induced Interstitial Lung Disease Caused by Epirubicin and Cyclophosphamide Therapy Before Breast Cancer Surgery
por: Egashira, Ayaka, et al.
Publicado: (2021)

The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
por: Liu, Deyue, et al.
Publicado: (2022)

Awareness among tertiary care doctors about Pharmacovigilance Programme of India: Do endocrinologists differ from others?
por: Sharma, Pramod Kumar, et al.
Publicado: (2016)

Bedaquiline versus placebo for management of multidrug-resistant tuberculosis: A systematic review
por: Singh, Surjit, et al.
Publicado: (2016)

Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response
por: Stevens, William, et al.
Publicado: (2021)

The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study
por: Russo, Francesco, et al.
Publicado: (2013)

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy
por: Li, Hai, et al.
Publicado: (2019)

Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
por: Kin, Takanori, et al.
Publicado: (2020)

High Serum Estradiol Reduces Acute Hepatotoxicity Risk Induced by Epirubicin Plus Cyclophosphamide Chemotherapy in Premenopausal Women with Breast Cancer
por: Huang, Shunmin, et al.
Publicado: (2021)

A prospective, cross-sectional study on association of serum vitamin D level with musculoskeletal symptoms and blood pressure in adult population
por: Singh, Vikram, et al.
Publicado: (2020)

Duloxetine-induced hypertensive urgency in type 2 diabetes mellitus with diabetic neuropathy
por: Shukla, Ravindra, et al.
Publicado: (2020)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures
por: Modlich, Olga, et al.
Publicado: (2005)

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
por: Yao, Xin, et al.
Publicado: (2012)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
por: Li, Fu, et al.
Publicado: (2023)

Hemorrhagic manifestation in different etiologies of pancytopenia: A prospective, cross-sectional study
por: Singh, Mridu, et al.
Publicado: (2021)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer: A Randomized Clinical Trial
por: Yuan, Peng, et al.
Publicado: (2023)

Knowledge, awareness and practice of ethics among doctors in tertiary care hospital
por: Singh, Surjit, et al.
Publicado: (2016)

Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
por: Kim, Jong Gwang, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_fk9rc01ehrr851d8jr23r6umra